帕金森病患者血清Lp-PLA2、S100β、sCD40L水平变化及与疾病分期、认知障碍的相关性  

Changes of serum Lp-PLA2, S100β and sCD40L levels in patients with Parkinson 's disease and their correlation with disease stage and cognitive impairment

作　　者：刘晓玲 卫锐 赵丰丽 LIU Xiao-ling;WEI Rui;ZHAO Feng-li(Department of Neurology,Yuncheng Central Hospital,Yuncheng Shanxi 044000,China)

机构地区：[1]运城市中心医院神经内科,山西运城044000

出　　处：《临床和实验医学杂志》2022年第23期2487-2491,共5页Journal of Clinical and Experimental Medicine

基　　金：山西省卫生健康委员会项目(编号:2020XM59)。

摘　　要：目的探讨帕金森病患者血脂蛋白相关磷脂酶A2(Lp-PLA2)、中枢神经特异性蛋白S100β、可溶性T淋巴细胞CD40配体(sCD40L)水平变化及与疾病分期、认知障碍的相关性。方法前瞻性选取2019年8月至2022年3月运城市中心医院收治的帕金森病患者117例病例资料,将其纳入观察组,并将同期50名健康体检人群纳入对照组。检测两组研究对象血清Lp-PLA2、S100β、sCD40L水平,并对帕金森病患者进行疾病分期和认知功能评估。其中,Ⅰ期16例,Ⅱ期32例,Ⅲ期36例,Ⅳ期34例,Ⅴ期9例;认知正常41例,认知障碍76例。观察不同疾病分期及是否伴有认知功能障碍帕金森病患者血清Lp-PLA2、S100β、sCD40L水平变化。并采用Spearman相关性检验进行相关性分析。结果观察组血清Lp-PLA2、S100β、sCD40L水平高于对照组,差异有统计学意义(P<0.05)。不同分期帕金森病患者血清Lp-PLA2、S100β、sCD40L水平差异有统计学意义(P<0.05);且Lp-PLA2、S100β、sCD40L水平随疾病分期增高呈上升趋势(P<0.05)。认知障碍帕金森病患者血清Lp-PLA2、S100β、sCD40L水平均高于认知正常患者,差异均有统计学意义(P<0.05)。Spearman相关性分析显示,Lp-PLA2、S100β、sCD40L水平表达与帕金森病患者疾病分期及认知功能呈正相关性(P<0.05)。结论Lp-PLA2、S100β、sCD40L水平在帕金森病患者血清中现高表达,且与帕金森病疾病分期、认知障碍具有相关性。Objective To investigate the changes of plasma lipoprotein-associated phospholipase A2(Lp-PLA2), central nervous specific protein S100β and soluble CD40 ligand(sCD40L) levels in patients with Parkinson ’s disease(PD) and their correlation with disease stage and cognitive impairment. Methods One hundred and seventeen patients with Parkinson ’s disease admitted to Yuncheng Central Hospital from August 2019 to March 2022 were selected and included in the observation group, and 50 healthy subjects were included in the control group during the same period. The levels of serum Lp-PLA2, S100β, and sCD40L were measured in both groups, and disease stage and cognitive function were assessed in Parkinson’s patients. There were 16 cases in stage Ⅰ, 32 cases in stage Ⅱ, 36 cases in stage Ⅲ, 34 cases in stage Ⅳ, and 9 cases in stage Ⅴ;41 cases with normal cognition and 76 cases with cognitive impairment. Changes in serum Lp-PLA2, S100β, and sCD40L levels were observed in parkinsonian patients with different disease stages and with or without cognitive dysfunction. Spearman correlation test was used for correlation analysis.Results The serum levels of Lp-PLA2, S100β and sCD40L in the observation group were higher than those in the control group(P<0.05). There were significant differences in serum Lp-PLA2, S100β, and sCD40L levels among patients with different stages of Parkinson’s disease(P<0.05). Lp-PLA2, S100 β, SCD40L levels tended to increase with higher disease stage(P<0.05). 76(64.96%) had cognitive impairment. Serum levels of Lp-PLA2, S100β and sCD40L were higher in Parkinson ’s patients with cognitive impairment than in cognitively normal patients(P<0.05). Spearman correlation analysis showed that Lp-PLA2, S100β and sCD40L level expression was positively correlated with disease stage and cognitive function in Parkinson’s patients(P<0.05). Conclusion Lp-PLA2, S100 β, SCD40L levels were found to be highly expressed in the serum of PD patients and correlated with PD disease stage and cognitiv

关 键 词：帕金森病 脂蛋白相关磷脂酶A2 S100Β蛋白 CD40配体 认知功能障碍 

分 类 号：R742.5[医药卫生—神经病学与精神病学]